会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明授权
    • Process for producing xanthine derivatives with bacteria and fungi
    • 用细菌和真菌生产黄嘌呤衍生物的方法
    • US6107064A
    • 2000-08-22
    • US581533
    • 1996-01-17
    • Junichi ShimadaTamotsu EguchiKenichi MochidaAkira HoriguchiTohru YasuzawaHideaki KusakaHiromi NonakaFumio Suzuki
    • Junichi ShimadaTamotsu EguchiKenichi MochidaAkira HoriguchiTohru YasuzawaHideaki KusakaHiromi NonakaFumio Suzuki
    • C07D473/04C07D473/06C12P17/18C12P17/16
    • C07D473/04C07D473/06C12P17/18
    • The present invention relates to a process for producing a xanthine derivative represented by formula (II), comprising converting a xanthine derivative represented by formula (I) {hereinafter, referred to as Compound (I)}: ##STR1## (wherein R.sup.1 and R.sup.2 independently represent hydrogen, or hydroxy-substituted, oxo-substituted, or unsubstituted lower alkyl) into a xanthine derivative represented by formula (II) {hereinafter, referred to as Compound (II)}: ##STR2## (wherein R.sup.3 and R.sup.4 independently represent hydrogen, or hydroxy-substituted, oxo-substituted, or unsubstituted lower alkyl; R.sup.5 and R.sup.6 independently represent hydrogen, hydroxy, or oxo; with the proviso that R.sup.5 and R.sup.6 are both hydrogen, at least one of R.sup.3 and R.sup.4 is hydroxy-substituted or oxo-substituted lower alkyl; and X and Y both represent hydrogen or are combined with each other to form a single bond) in the presence of an enzyme source for catalyzing hydroxylation or carbonylation of Compound (I) into Compound (II), and collecting the produced Compound (II).
    • PCT No.PCT / JP95 / 00929 Sec。 371日期1996年1月17日 102(e)日期1996年1月17日PCT提交1995年5月16日PCT公布。 公开号WO95 / 31460 日本特开平9-1252号公报发明内容本发明涉及由式(II)表示的黄嘌呤衍生物的制造方法,其特征在于,将由式(I)表示的黄嘌呤衍生物{以下称为化合物(I)} 和R2独立地表示氢或羟基取代的,取代或未取代的低级烷基)转化为由式(II)表示的黄嘌呤衍生物(以下称为化合物(II)}:(其中R 3和R 4独立地表示氢 或羟基取代的,取代或未取代的低级烷基; R 5和R 6独立地表示氢,羟基或氧代;条件是R 5和R 6都是氢,R 3和R 4中的至少一个是羟基取代的或 氧代取代的低级烷基; X和Y均表示氢或彼此结合形成单键)在用于催化化合物(I)羟化或羰基化成化合物(II)的酶源的存在下,以及大学 将所制备的化合物(II)。
    • 10. 发明授权
    • Condensed purine derivatives
    • 凝血嘌呤衍生物
    • US06306847B1
    • 2001-10-23
    • US09090936
    • 1998-06-05
    • Hiroshi TsumukiMayumi SakiHiromi NonakaMichio IchimuraJunichi ShimadaFumio SuzukiShunji IchikawaNobuo Kosaka
    • Hiroshi TsumukiMayumi SakiHiromi NonakaMichio IchimuraJunichi ShimadaFumio SuzukiShunji IchikawaNobuo Kosaka
    • C07D48714
    • C07D487/14
    • The present invention provides condensed purine derivatives or pharmacologically acceptable salts thereof exhibiting adenosine A3 acceptor antagonising activity, and having an antiasthmatic action, a bronchodilator action, an antiantiitching action, etc., and represented by the following formula (I): (wherein R1 represents substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; R2 represents hydrogen, lower alkyl, alicyclic alkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or a substituted or unsubstituted aromatic heterocyclic group; R3 represents hydrogen, lower alkyl, or substituted or unsubstituted aralkyl; X1 and X2 are the same or different and each represents hydrogen, lower alkyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted aryl; and n represents an integer of 0 to 3).
    • 本发明提供具有腺苷A3受体拮抗活性的缩合嘌呤衍生物或其药理学上可接受的盐,并具有抗哮喘作用,支气管扩张剂作用,抗脱除作用等,并由下式(I)表示:(其中R1表示 取代或未取代的芳基或取代或未取代的芳族杂环基; R 2表示氢,低级烷基,脂环族烷基,取代或未取代的芳烷基,取代或未取代的芳基或取代或未取代的芳族杂环基; R 3表示氢,低级烷基或 取代或未取代的芳烷基; X 1和X 2相同或不同,各自表示氢,低级烷基,取代或未取代的芳烷基或取代或未取代的芳基; n表示0〜3的整数。